Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 1 562 JPY -0.64% Market Closed
Market Cap: 2.8T JPY
Have any thoughts about
Astellas Pharma Inc?
Write Note

Astellas Pharma Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Astellas Pharma Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Astellas Pharma Inc
TSE:4503
Short-Term Investments
ÂĄ35.7B
CAGR 3-Years
106%
CAGR 5-Years
55%
CAGR 10-Years
1%
Takeda Pharmaceutical Co Ltd
TSE:4502
Short-Term Investments
ÂĄ47.2B
CAGR 3-Years
22%
CAGR 5-Years
28%
CAGR 10-Years
-11%
Daiichi Sankyo Co Ltd
TSE:4568
Short-Term Investments
ÂĄ140.8B
CAGR 3-Years
-14%
CAGR 5-Years
-23%
CAGR 10-Years
-6%
Otsuka Holdings Co Ltd
TSE:4578
Short-Term Investments
ÂĄ91.1B
CAGR 3-Years
54%
CAGR 5-Years
5%
CAGR 10-Years
-6%
S
Shionogi & Co Ltd
TSE:4507
Short-Term Investments
ÂĄ272.5B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
17%
Chugai Pharmaceutical Co Ltd
TSE:4519
Short-Term Investments
ÂĄ301.7B
CAGR 3-Years
14%
CAGR 5-Years
23%
CAGR 10-Years
10%
No Stocks Found

Astellas Pharma Inc
Glance View

Market Cap
2.8T JPY
Industry
Pharmaceuticals

Astellas Pharma Inc., a prominent player in the global pharmaceutical industry, has a clear mission: to improve the health of people around the world through innovative technologies and high-quality products. Founded in 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established itself as a leader in areas such as urology, oncology, immunology, and neuroscience. With strong research and development capabilities, the company invests heavily in developing groundbreaking therapies that address unmet medical needs, positioning itself at the forefront of advancements in health sciences. Astellas prides itself on its commitment to sustainability, ensuring that its operations positively impact society while delivering substantial value to shareholders. For investors, Astellas represents a compelling opportunity, given its strong financial footing and robust product pipeline. The company boasts a diverse portfolio with several key blockbuster drugs contributing to its steady revenue stream, alongside a promising array of candidates in clinical trials. Furthermore, Astellas actively pursues strategic partnerships and acquisitions to bolster its R&D initiatives and expand its global reach. With a focus on maximizing shareholder value through disciplined financial management and a strategic approach to innovation, Astellas Pharma is not just navigating the complexities of the pharmaceutical landscape; it is shaping the future of healthcare, making it a noteworthy consideration for investors looking for growth in the biotech sphere.

Intrinsic Value
1 795.96 JPY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Astellas Pharma Inc's Short-Term Investments?
Short-Term Investments
35.7B JPY

Based on the financial report for Jun 30, 2024, Astellas Pharma Inc's Short-Term Investments amounts to 35.7B JPY.

What is Astellas Pharma Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
1%

Over the last year, the Short-Term Investments growth was -14%. The average annual Short-Term Investments growth rates for Astellas Pharma Inc have been 106% over the past three years , 55% over the past five years , and 1% over the past ten years .

Back to Top